GPRC5D

Assets acting on this target.

Class
GPRC5D-directed

GPRC5D is an orphan G protein-coupled receptor, meaning it belongs to a large family of cell-surface signaling proteins but its natural activating molecule remains unidentified. What makes it useful in medicine is not its signaling function but its pattern of expression: it is displayed at high density on malignant plasma cells in multiple myeloma, a cancer of antibody-producing immune cells, while being largely absent from most other tissues in the body. This selective expression allows it to serve as a marker that immune-based therapies can use to distinguish tumor cells from healthy ones. Modulating this target does not aim to block a signaling pathway, as with many drugs, but rather to flag GPRC5D-bearing cells for destruction by engineered immune cells or targeted biologic agents. This approach is particularly relevant for multiple myeloma patients whose disease has stopped responding to therapies directed at other plasma cell markers, since GPRC5D offers an independent point of attack. Because the receptor's biology outside plasma cells is limited to a small number of tissues, therapies against it can achieve meaningful tumor cell elimination with a relatively contained range of effects on normal tissue, though not without consequence, as detailed in the deeper explanation.

By indication

Related mechanisms

GPRC5D drugs compared

7 drugs, stage by indication
7 drugs acting on GPRC5D: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Arlocabtagene autoleucelBristol-Myers Squibb, Juno Therapeutics, Inc.CAR-T cell therapyPhase 3Phase 3 in Multiple Myeloma
CT071CARsgen Therapeutics Holdings LimitedCAR-T cell therapyPhase 1/2Phase 1/2 in Multiple Myeloma
OriCAR-017OriCell Therapeutics Co., Ltd.CAR-T (autologous, GPRC5D-directed)Phase 1/2Phase 1/2 in Multiple Myeloma
Vemzatatug vedotinAstraZenecaantibody-drug conjugate (anti-GPRC5D)Phase 1/2Phase 1/2 in Multiple Myeloma
CAR-GPRC5D (RD118, IASO Biotherapeutics)IASO BiotherapeuticsCAR-T cell therapyPhase 1Phase 1 in Multiple Myeloma
JNJ-87562761Johnson & Johnsonmonoclonal antibodyPhase 1Phase 1 in Multiple Myeloma
SAR446523Sanofimonoclonal antibodyPhase 1Phase 1 in Multiple Myeloma

← all mechanisms